Articles

On October 23, 2020, the FDA approved the FoundationOne CDx diagnostic test as a companion diagnostic to identify fusions in the NTRK1, NTRK2, and NTRK3 genes in patients who are eligible for treatment with larotrectinib (Vitrakvi).

Although chimeric antigen receptor (CAR) T-cell therapy has been a life-saving treatment for some patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other hematologic malignancies, additional therapies may be able to perform equally well in select patients, according to Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center, New York City. Dr Zelenetz spoke at the 2020 NCCN hematologic malignancies conference.

Although smoldering myeloma is acknowledged as a clinical entity, debate continues about whether to treat, when to treat, and how to treat this condition, said Natalie S. Callander, MD, Leader, Myeloma/Lymphoma Disease-Oriented Team, University of Wisconsin Carbone Cancer Center, Madison, at the 2020 NCCN hematologic malignancies conference.

At the 2020 NCCN hematologic malignancies conference, multiple myeloma expert Shaji Kumar, MD, Consultant and Professor of Medicine, Division of Hematology, Mayo Clinic Cancer Center, Rochester, MN, discussed the “bonanza of treatment regimens for multiple myeloma.”

Enrollment in clinical trials is vital for the advancement of knowledge and improvement of patient outcomes, but few adults participate in cancer clinical trials. The numbers are even lower among minority adolescent and young adults (AYAs).

Total growth in the oncology pipeline in 2020 has been driven by targeted therapies, said Doug Long, Vice President, Industry Relations, IQVIA, at the 10th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2020.

The COVID-19 pandemic has exposed many of the cracks in our healthcare system. According to Maurie Markman, MD, MS, FACP, FASCO, President, Medicine and Science, Cancer Treatment Centers of America, COVID-19 disproportionately affects the elderly, those with comorbidities, and racial and ethnic minority populations, all of whom are more likely to have serious or fatal illness. At the 10th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2020, Dr Markman served as a co-moderator of a session about minority representation in clinical trials.

Greg Simon, JD, led the Cancer Moonshot program for the Obama administration, raising $1.8 billion in new funding for cancer research and the development of new cancer programs. In 2017, Joe Biden called on him to serve as President of the Biden Cancer Initiative. Mr Simon is also a survivor of chronic lymphocytic leukemia, a consultant and public speaker at Simonovation, LLC, and one of the thought leaders in cancer care.

In an environment of increasing vertical and horizontal integration in healthcare, are new value-based care models in oncology—such as the Centers for Medicare & Medicaid Services’ pilot payment project, the Oncology Care Model (OCM)—working? Five years from now, will we still be talking about efforts to go from volume to value using alternative payment models?

The COVID-19 pandemic has spurred adjustments to the current Oncology Care Model (OCM) and is also affecting considerations for future models, according to Lara Strawbridge, MPH, Director, Division of Ambulatory Payment Models, Center for Medicare and Medicaid Innovation, who delivered the keynote address at the 2020 NCCN Oncology Policy Summit.